This is an economic evaluation that meets the criteria for inclusion on NHS EED. A CRD commentary can be requested using the button above.
Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer . Annals of Internal Medicine 2010; 152(10): 621-629
Subject indexing assigned by NLM
Aged; Aged, 80 and over; Alendronate /adverse effects /therapeutic use; Androgen Antagonists /adverse effects; Antineoplastic Agents /adverse effects; Bone Density; Bone Density Conservation Agents /adverse effects /therapeutic use; Combined Modality Therapy; Computer Simulation; Cost-Benefit Analysis; Disease Progression; Gonadotropin-Releasing Hormone /agonists; Hip Fractures /prevention & Humans; Male; Markov Chains; Middle Aged; Orchiectomy /adverse effects; Osteoporosis /complications; Prostatic Neoplasms /physiopathology /therapy; Quality-Adjusted Life Years; Risk Factors; control
Date bibliographic record published